Axplora, a partner to Pharma companies and Biotechs for complex APIs, is investing €8 million to expand capacity for antibody drug conjugate payload manufacturing at its Le Mans site in France, to deliver life-changing cancer treatments for patients.
This investment creates a new production suite for antibody drug conjugate payload manufacturing, to enable innovative pharmaceutical partners to develop the next generation of targeted therapies in oncology.
This new suite will allow Axplora to produce various payloads at kilogram scale to secure the supply of API for customers. It has been designed to operate over a wide range of process conditions with best-in-class process equipment and containment technology. In addition, at least 15 new positions will be created to support the site.
“This increased capacity is the result of our long-term strategy of growing in a sustainable manner, with the commitment to provide more efficient and optimized manufacturing processes to secure the supply chain of our customers,” says Rachel De Luca, Site Director in Le Mans.
“We are proud to develop tomorrow’s anticancer drugs to treat patients and confident that this investment will open up new opportunities to fight against cancer together with agility and reliability.”
“We welcome the support of the French government which allow us to accelerate our development and broaden our offering to our customers,” adds Philippe Gaucher, Technical Director. “We are pleased to be part of the National program to encourage the development of biopharmaceuticals – France 2030 – and to strengthen our position to develop and produce innovative anticancer drugs in France.”
